Canlyniadau Chwilio - Navdeep Pal

  • Dangos 1 - 8 canlyniadau o 8
Mireinio'r Canlyniadau
  1. 1
    Overall survival in patients with advanced non-small cell lung cancer with KRAS G12C mutation with or without STK11 and/or KEAP1 mutations in a real-world setting

    Overall survival in patients with advanced non-small cell lung cancer with KRAS G12C mutation with or without STK11 and/or KEAP1 mutations in a real-world setting gan Cristina Julián, Navdeep Pal, Anda Gershon, Marie Evangelista, Hans E. Purkey, Peter Lambert, Zhen Shi, Qing Zhang

    Cyhoeddwyd 2023
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  2. 2
    Overall survival after pelvic exenteration for gynecologic malignancy

    Overall survival after pelvic exenteration for gynecologic malignancy gan Shannon N. Westin, Vijayashri Rallapalli, Bryan Fellman, Diana L. Urbauer, Navdeep Pal, Michael Frumovitz, Lois M. Ramondetta, Diane C. Bodurka, Pedro T. Ramírez, Pamela T. Soliman

    Cyhoeddwyd 2014
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  3. 3
    Evaluating eligibility criteria of oncology trials using real-world data and AI

    Evaluating eligibility criteria of oncology trials using real-world data and AI gan Ruishan Liu, Shemra Rizzo, Samuel Whipple, Navdeep Pal, Arturo López Pineda, Michael W. Lu, Brandon Arnieri, Ying Lü, William B. Capra, Ryan Copping, James Zou

    Cyhoeddwyd 2021
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  4. 4
    Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small-cell lung cancer (Nsq-NSCLC) with PD-L1-high expression using real-world data

    Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small-cell lung cancer (Nsq-NSCLC) with PD-L1-hig... gan M. Pérol, Enriqueta Felip, Urania Dafni, Letizia Polito, Navdeep Pal, Zoi Tsourti, Thanh G.N. Ton, David M. Merritt, S. Morris, Rolf A. Stahel, Solange Peters

    Cyhoeddwyd 2022
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  5. 5
    Systematic analysis of off-label and off-guideline cancer therapy usage in a real-world cohort of 165,912 US patients

    Systematic analysis of off-label and off-guideline cancer therapy usage in a real-world cohort of 165,912 US patients gan Ruishan Liu, Lisa Wang, Shemra Rizzo, Marius Garmhausen, Navdeep Pal, Sarah Waliany, Sarah F. McGough, Yvonne G. Lin, Zhi Huang, Joel W. Neal, Ryan Copping, James Zou

    Cyhoeddwyd 2024
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  6. 6
    Treatment of Low-Risk Endometrial Cancer and Complex Atypical Hyperplasia With the Levonorgestrel-Releasing Intrauterine Device

    Treatment of Low-Risk Endometrial Cancer and Complex Atypical Hyperplasia With the Levonorgestrel-Releasing Intrauterine Device gan Navdeep Pal, Russell R. Broaddus, Diana L. Urbauer, Nyla Balakrishnan, Andrea Milbourne, Kathleen M. Schmeler, Larissa A. Meyer, Pamela T. Soliman, Karen H. Lu, Pedro T. Ramírez, Lois M. Ramondetta, Diane C. Bodurka, Shannon N. Westin

    Cyhoeddwyd 2017
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  7. 7
    PTEN loss is a context-dependent outcome determinant in obese and non-obese endometrioid endometrial cancer patients

    PTEN loss is a context-dependent outcome determinant in obese and non-obese endometrioid endometrial cancer patients gan Shannon N. Westin, Zhenlin Ju, Russell R. Broaddus, Camilla Krakstad, Jane Li, Navdeep Pal, Karen H. Lu, Robert L. Coleman, Bryan T. Hennessy, Samuel J. Klempner, Henrica M.J. Werner, Helga B. Salvesen, Lewis C. Cantley, Gordon B. Mills, Andrea P. Myers

    Cyhoeddwyd 2015
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  8. 8
    Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer

    Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer gan Shannon N. Westin, Bryan Fellman, Charlotte C. Sun, Russell R. Broaddus, Misty Woodall, Navdeep Pal, Diana L. Urbauer, Lois M. Ramondetta, Kathleen M. Schmeler, Pamela T. Soliman, Nicole D. Fleming, Jennifer K. Burzawa, Alpa M. Nick, Andrea Milbourne, Ying Yuan, Karen H. Lu, Diane C. Bodurka, Robert L. Coleman, Melinda S. Yates

    Cyhoeddwyd 2020
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:

Offerynnau Chwilio: